Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3 , Pages 258-262 , May 2009

The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Gúerin immunotherapy

  • Ofer N. Gofrit, M.D., Ph.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    • Department of Surgery, Section of Urology, Chicago University Hospital, Chicago, IL 60637, USA
    • Corresponding Author InformationCorresponding author. Tel.: +972-2-6776874; fax: +972-2-6430929
    • ,
  • Dov Pode, M.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    • ,
  • Galina Pizov, M.D.

      Affiliations

    • Department of Pathology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    • ,
  • Kevin C. Zorn, M.D.

      Affiliations

    • Department of Surgery, Section of Urology, Chicago University Hospital, Chicago, IL 60637, USA
    • ,
  • Ran Katz, M.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    • ,
  • Mordechi Duvdevani, M.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Hospital, Jerusalem, Israel
    • ,
  • Amos Shapiro, M.D.

      Affiliations

    • Department of Urology, Hadassah Hebrew University Hospital, Jerusalem, Israel

Received 6 November 2007 ,Revised 13 December 2007 ,Accepted 13 December 2007.

References 

  1. Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am. 1999;26:493–507
  2. Sanchez-Fernandez de Sevilla MC, Morell-Quadreny L, Gil-Salom M, et al. Morphometric and immunohistochemical characterization of bladder carcinoma in situ and its preneoplastic lesions. Eur Urol. 1992;21(1):5–9
  3. Brawn PN. The origin of invasive carcinoma of the bladder. Cancer. 1982;50:515–519
  4. Lee R, Droller MJ. The natural history of bladder cancer (Implications for therapy). Urol Clin North Am. 2000;27:1–13
  5. Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–1264
  6. Skinner DG, Richie JP, Cooper PH, et al. The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma. J Urol. 1974;112:68–71
  7. Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes (A study of the urothelium in ten surgically removed bladders). JAMA. 1974;227:281–286
  8. Althausen AF, Prout GR, Daly JJ. Noninvasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol. 1976;116:575–580
  9. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol. 1995;153:564–572
  10. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Gúerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325:1205–1209
  11. de Reijke TM, Kurth KH, Sylvester RJ, et al. Bacillus Calmette-Gúerin vs. epirubicin for primary, secondary, or concurrent carcinoma in situ of the bladder: Results of a European Organization for the Research and Treatment of Cancer, Genito-Urinary Group, Phase III trial (30906). J Urol. 2005;173:405–409
  12. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus Calmette-Guérin vs. chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder (A meta-analysis of the published results of randomized clinical trials). J Urol. 2005;174:86–91
  13. Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Gúerin therapy for superficial bladder cancer (A 10-year followup). J Urol. 1992;147:1020–1023
  14. Prout GR, Griffin PP, Daly JJ, et al. Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms. Cancer. 1983;52:524–532
  15. Orozco RE, Martin AA, Murphy WM. Carcinoma in situ of the urinary bladder (Clues to host involvement in human carcinogenesis). Cancer. 1994;74:115–122
  16. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer. 1999;85:2469–2474
  17. Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: Long-term results of EORTC GU Group Phase II protocol 30861. Eur Urol. 2001;40:144–150
  18. Herr HW, Badalament RA, Amato DA, et al. Superficial bladder cancer treated with bacillus Calmette-Gúerin: A multivariate analysis of factors affecting tumor progression. J Urol. 1989;141:22–29
  19. Mostofi FK, Sobin LH, Torloni H. International histological classification of tumors, No 10 (Histological typing of urinary bladder tumors). Geneva: World Health Organization; 1973;
  20. Haaff EO, Dresner SM, Ratliff TL, et al. Two courses of intravesical bacillus Calmette-Gúerin for transitional cell carcinoma of the bladder. J Urol. 1986;136:820–824
  21. Malkowicz SB, Nichols P, Lieskovsky G, et al. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS, and P2). J Urol. 1990;144:641–645
  22. Jenkins BJ, England HR, Fowler CG, et al. Chemotherapy for carcinoma in situ of the bladder. Br J Urol. 1988;61:326–329
  23. Kaasinen E, Wijkström H, Malmström PU, et al. Alternating mitomycin C and BCG instillations vs. BCG alone in treatment of carcinoma in situ of the urinary bladder: A Nordic study. Eur Urol. 2003;43:637–645
  24. Merz VW, Marth D, Kraft R, et al. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Gúerin for carcinoma in situ of the bladder. Br J Urol. 1995;75:180–184
  25. Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res. 1999;5:4079–4084
  26. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer. 2007;109:1499–1505
  27. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Gúerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol. 2000;163:1124–1129
  28. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Gúerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–1970

PII: S1078-1439(07)00332-8

doi: 10.1016/j.urolonc.2007.12.011

Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3 , Pages 258-262 , May 2009

Article Tools

* Image Usage & Resolution